España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Takeda Pharmaceutical Co
TAK
NYSE
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$13.39
-0.31
-2.26%
At close: -
$13.53
0.14
1.05%
After Hours: Jan 31, 9:29 AM EDT
Get Report
Comment
Q3 2024 Earnings were released on Thu Jan 30th, before the market open
The most recent conference call was at 5:30 AM, 2 days ago
Click to view past webcast
Takeda Pharmaceutical Co (TAK) Forecast
News
Earnings
Takeda Pharmaceutical Co (TAK) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Takeda Pharmaceutical Co (NYSE:TAK) Stock
Takeda Pharmaceutical Co Stock (NYSE: TAK)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, January 30, 2025
Takeda Pharmaceutical shares are trading high...
Benzinga Newsdesk
Earnings Scheduled For January 30, 2025
Benzinga Insights
Takeda Announces Share Buyback Of Up To JPY 1...
Benzinga Newsdesk
Takeda FY2024 Guidance Raised: Core Revenue A...
Benzinga Newsdesk
Takeda Names Julie Kim As Next CEO, Succeedin...
Benzinga Newsdesk
Takeda Pharmaceutical Q3 2024 GAAP EPS ¥15.01...
Benzinga Newsdesk
Wednesday, January 29, 2025
Takeda Announces HyQvia Added To Héma-Québec'...
Benzinga Newsdesk
Tuesday, January 28, 2025
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
Vandana Singh
Monday, January 27, 2025
Neurocrine Biosciences Amends Agreement With ...
Benzinga Newsdesk
Tuesday, January 21, 2025
Keros Therapeutics Global License Agreement W...
Benzinga Newsdesk
Reported Monday, Takeda's FRUZAQLA (fruquinti...
Benzinga Newsdesk
Wednesday, January 15, 2025
FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks: Food Stocks To Watch
Maureen Meehan
Friday, December 27, 2024
Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency
Nabaparna Bhattacharya
Takeda Gains Approval For HYQVIA In Japan To ...
Benzinga Newsdesk
Wednesday, December 18, 2024
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Vandana Singh
Friday, December 13, 2024
Reported Earlier, HUTCHMED to Receive $10M Pa...
Benzinga Newsdesk
Thursday, December 12, 2024
Takeda Plans To Host An Investor R&D Day; Exp...
Benzinga Newsdesk
Tuesday, December 03, 2024
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
Vandana Singh
Takeda Tapped Keros Therapeutics Under A $200...
Benzinga Newsdesk
Wednesday, November 20, 2024
Alloy Therapeutics Signs Collaboration And Li...
Benzinga Newsdesk
Thursday, November 14, 2024
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
Vandana Singh
Tuesday, November 12, 2024
Urgency, Debate Mark COP29 As Leaders Push For Carbon Market Rules, Worry About Trump
Stjepan Kalinic
Thursday, October 31, 2024
Takeda Raises 2024 Outlook: Now Expects Reven...
Benzinga Newsdesk
Takeda Pharmaceutical Q2 2024 GAAP EPS ¥134.0...
Benzinga Newsdesk
Wednesday, October 30, 2024
Preview: Takeda Pharmaceutical's Earnings
Benzinga Insights
Thursday, October 17, 2024
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
Vandana Singh
Wednesday, October 09, 2024
Reported Earlier, Takeda, Astellas, And SMBC ...
Benzinga Newsdesk
Friday, October 04, 2024
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
Vandana Singh
Thursday, September 26, 2024
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
MarketBeat
Tempus With Takeda Announces Expansion Of Col...
Benzinga Newsdesk
Tuesday, September 24, 2024
Takeda's FRUZAQLA Capsules Approved in Japan ...
Benzinga Newsdesk
Thursday, September 19, 2024
Takeda To Present Additional Clinical Trial S...
Benzinga Newsdesk
Monday, September 16, 2024
Vatroslav Mateljic Appointed General Manager ...
Benzinga Newsdesk
Tuesday, September 10, 2024
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
Vandana Singh
Monday, September 09, 2024
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Vandana Singh
Friday, September 06, 2024
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
Vandana Singh
Monday, August 12, 2024
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
Vandana Singh
Wednesday, August 07, 2024
Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
Vandana Singh
Takeda shares are trading higher after the Eu...
Benzinga Newsdesk
The European Commission Approves Takeda's Adz...
Benzinga Newsdesk
Wednesday, July 31, 2024
Takeda 2024 Outlook, Reaffirmed: Expects Reve...
Benzinga Newsdesk
Takeda Pharmaceutical Q1 Core EPS ¥176 Up Fro...
Benzinga Newsdesk
Wednesday, July 24, 2024
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Vandana Singh
Thursday, July 18, 2024
Dr. Reddy's Signs Non-Exclusive Patent Licens...
Benzinga Newsdesk
Tuesday, July 09, 2024
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Vandana Singh
Tuesday, July 02, 2024
Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report
Lekha Gupta
Monday, June 24, 2024
FDA Expands Argenx's Vyvgart Label to Treat Rare Disorder
Zacks
Takeda's LIVTENCITY Gains Approval in Japan f...
Benzinga Newsdesk
Reported Earlier, Takeda's Mezagitamab Shows ...
Benzinga Newsdesk
Friday, June 21, 2024
Takeda Announces European Commission Approval...
Benzinga Newsdesk
Show More